Rejected at 6:36 p.m. Dec, 29, 2023 ] by herstein.jacob
Author: andresspy
Related Note: 1509297958448
Rationale for change

Amboss calls Osimertinib a first line agent for NSCLC https://next.amboss.com/us/search?q=Osimertinib&v=overview and does not call Erlotinib first line anywhere https://next.amboss.com/us/search?q=Erlotinib&v=overview

Rejection reason

See discussion - also, the wording here is that erlotinib is a first-line tx, not THE first-line tx (i.e., not the only option), so not technically wrong

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy



Watch Kinase Inhibitors
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo

Bootcamp
Watch associated Bootcamp video - Cellular Injury and Neoplasia: Cell Cycle Independent Drug Targets Watch associated Bootcamp video - Principles of Oncology and Therapeutics: Cell Cycle Independent Drug Targets
OME

Additional Resources
Empty field
One by one
Empty field
!AK_UpdateTags::Step1decks::Lolnotacop::Drugs #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::03_Kinase_Inhibitors_&_Monoclonal_Antibodies::01_Kinase_Inhibitors #AK_Step1_v12::#FirstAid::10_Hematology_Oncology::05_Pharm::20_Erlotinib #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::#OME_banner #AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::16_Imatinib_Dasatinib_Nilotinib_Dabrafenib_Vemurafenib #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::16_Erlotinib #AK_Step1_v12::#AMBOSS::RTalqP